Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy

Overview
This review groups autologous cancer cell therapies into four classes and sets out the engineering hurdles of each. Long manufacturing times, specialized expansion processes and quality control come up across all of them.
What this paper found
Autologous cell therapies for cancer fall into four classes: CAR T cells, tumor-infiltrating lymphocytes, dendritic cell vaccines and whole tumor cell vaccines. Each class faces distinct engineering hurdles. CAR T cells need efficient, multiplexed gene editing and more consistent products, while TIL therapy needs simpler, faster manufacturing and less exhaustion. DC vaccines require better cell sources, antigen loading and lymph node trafficking, and tumor cell vaccines need wider patient eligibility and consistent genetic modification. Across all four, the review identifies long manufacturing times, specialized expansion processes, quality control, trafficking, and toxicity from cytokines or lymphodepletion as shared challenges, and it describes engineering solutions for each.
Note: This is a narrative review of published work; it reports no new experiments.
Regardless of cell type for each therapy, there are innate manufacturing challenges in deriving a personalized therapeutic from patient cells. — Colleen R Foley, Sheridan L Swan, Melody A Swartz, The Journal of Immunology
Study details
- Authors
- Colleen R Foley, Sheridan L Swan, Melody A Swartz
- Institution
- Pritzker School of Molecular Engineering, University of Chicago, Chicago, Illinois · Committee on Immunology, University of Chicago, Chicago, Illinois · Ben May Department of Cancer Research, University of Chicago, Chicago, Illinois
- Journal
- The Journal of Immunology
- Year
- 2024
- Cell type(s)
- CAR T Cells, DC Cells, TIL Cells
- Application area
- Hematologic malignancy · Solid tumor
Explore related
Full citation
Foley CR, Swan SL, Swartz MA. Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy. J Immunol. 2024;212(2):188-198.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.